Leerink Partners Maintains Outperform on Arcus Biosciences, Raises Price Target to $49
Truist Securities Maintains Buy on Arcus Biosciences, Lowers Price Target to $40
Wedbush Maintains Outperform on Arcus Biosciences, Lowers Price Target to $45
Arcus Biosciences, Inc. Reports Third-Quarter 2026 Financial Results
Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update
Arcus Biosciences Q3 EPS $(1.00) Misses $(0.90) Estimate, Sales $9.000M Beat $8.305M Estimate
Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London
Arcus Biosciences Announces New Employment Inducement Grants
How Investors May Respond To Arcus Biosciences (RCUS) $250 Million Share Sale
Arcus Biosciences (RCUS) Stock Looks Stretched As Casdatifan Trial Data Impresses
Arcus Biosciences, Inc. Closes Public Offering of 16,428,572 Shares of Common Stock for Net Proceeds of Approximately $269.7 million
Arcus Biosciences, Inc. Estimates $694.0 million in Cash, Cash Equivalents and Marketable Securities as of September 30, 2026
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Arcus Biosciences stock falls on public offering announcement
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
Arcus Biosciences Commences Public Offering of Common Stock; Size Not Disclosed
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $50
Truist Securities Maintains Buy on Arcus Biosciences, Raises Price Target to $41
Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor Day
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $49
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.